Palladios — Next-Generation Non-Staining Topical Caries Arrest
Next-Generation Caries Arrest

The Strategic Defense Against Dental Decay

The first non-staining noble-metal coordination complex engineered to arrest active dental caries, occlude dentin tubules, and eliminate the drill—with zero aesthetic compromise.

Request Executive Briefing The Science

The Paradigm Shift in Operative Dentistry

Resolving the 50-year trade-off between clinical efficacy and aesthetic disfigurement.

The Current Standards

  • The Drill-and-Fill Treadmill: Invasive, aerosol-generating, and causes severe anxiety in pediatric and vulnerable patients. Fillings inevitably fail.
  • Conventional Fluorides: Assist superficial enamel remineralization, but lack the antimicrobial potency to arrest active cavitated dentin decay.
  • Silver Diamine Fluoride (SDF): Proven ~80% caries arrest, but permanently stains affected tooth structure jet-black, leading to massive patient and clinical rejection.

The Palladios™ Standard

  • 100% Aesthetic Preservation: Proven zero detectable staining under clinical photo-curing challenge. Complete natural tooth shade preservation.
  • Superior Sustained Biocidal Action: Outperformed 38% SDF in 5-day disc diffusion assays against polymicrobial human oral flora (20 mm vs. 14 mm).
  • Dense Tubule Occlusion: 100x microscopy confirms physical dentin tubule occlusion (<30 µm boundary), establishing an impermeable hydrodynamic fluid barrier.
  • Painless 60-Second Application: Water-based topical delivery with zero caustic ammonia fumes or unpleasant taste.

Engineered for Clinical Translation

A rigorous regulatory and intellectual property foundation.

Proprietary Chemistry

Protected by pending U.S. Patent claims covering noble-metal coordination complexes (tetraamminepalladium(II) fluoride monohydrate) stabilized by an extensive 12-donor hydrogen-bonding lattice.

De-Risked 510(k) Pathway

Targeting the established FDA Class II Medical Device pathway (21 CFR § 872.3260, Cavity Varnish / Dentin Desensitizer), mirroring the regulatory predicate of Advantage Arrest.

Translational Grant Track

Actively preparing for NIH/NIDCR SBIR Phase I translational studies focusing on ISO 10993-5 in vitro cytotoxicity and Pashley hydraulic conductance models.

Leadership & Inquiries

Matthew Hall — Founder & Lead Inventor. A dental clinician and researcher dedicated to transforming minimally invasive cariology and advancing painless, non-staining therapeutics for pediatric, geriatric, and high-anxiety patients.

For accelerator partnerships, scientific collaborations, or accredited investor inquiries:

Contact Matthew Hall Matthew Hall on LinkedIn